May 12, 2026 CRISPR-Edited CD33-Negative Cells and Gemtuzumab Ozogamicin: First-in-Human Trial Results
May 10, 2026 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
